Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company will present the latest clinical data and...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company and its collaborators present clinical data strongly ...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company and its collaborators have published a new research...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company has demonstrated more evidence for disease...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company has demonstrated evidence for disease modification...
OrthoTrophix, Inc., a privately-held biopharmaceutical company, announced today new analyses from a Phase 2 study of TPX-100, the company's...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company and its collaborators presented the Phase 2 clinical ...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company and its collaborators will present a late breaking...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today results of a post-hoc responder analysis of the Phase 2 clinical...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company plans to report long-term clinical benefits in mild...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company and its collaborators present the key data of the...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today the results of the first proof of principle study of TPX-100 in...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company completed subject enrollment and all scheduled...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today the completion of the dose-finding (Part A) portion of the Phase 2...
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company started a Phase 2 clinical study of its cartilage...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.